HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Abstract
On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.
AuthorsAnkit J Kansagra, Noelle V Frey, Merav Bar, Theodore W Laetsch, Paul A Carpenter, Bipin N Savani, Helen E Heslop, Catherine M Bollard, Krishna V Komanduri, Dennis A Gastineau, Christian Chabannon, Miguel A Perales, Michael Hudecek, Mahmoud Aljurf, Leslie Andritsos, John A Barrett, Veronika Bachanova, Chiara Bonini, Armin Ghobadi, Saar I Gill, Joshua Hill, Saad Kenderian, Partow Kebriaei, Arnon Nagler, David Maloney, Hien D Liu, Nirali N Shah, Mohamed A Kharfan-Dabaja, Elizabeth J Shpall, Ghulam J Mufti, Laura Johnston, Elad Jacoby, Ali Bazarbachi, John F DiPersio, Steven Z Pavletic, David L Porter, Stephan A Grupp, Michel Sadelain, Mark R Litzow, Mohamad Mohty, Shahrukh K Hashmi
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (Biol Blood Marrow Transplant) Vol. 25 Issue 3 Pg. e76-e85 (03 2019) ISSN: 1523-6536 [Electronic] United States
PMID30576834 (Publication Type: Journal Article)
CopyrightCopyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antigens, CD19
  • Receptors, Antigen, T-Cell
  • tisagenlecleucel
Topics
  • Antigens, CD19 (immunology)
  • Child
  • Critical Pathways
  • Drug Approval
  • Expert Testimony
  • Humans
  • Immunotherapy, Adoptive (methods)
  • Practice Patterns, Physicians'
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (therapy)
  • Receptors, Antigen, T-Cell (therapeutic use)
  • Societies, Medical
  • United States
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: